Differentiation therapy exerts antitumor effects on stem-like glioma cells

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2715-2728

  Campos, Benito ^a   Wan, Feng ^a,c   Farhadi, Mohammad ^a   Ernst, Aurélie ^b   Zeppernick, Felix ^a   Tagscherer, Katrin E ^b   Ahmadi, Rezvan ^a   Lohr, Jennifer ^a   Dictus, Christine ^a   Gdynia, Georg ^b   Combs, Stephanie E ^a   Goidts, Violaine ^b   Helmke, Burkhard M ^a   Eckstein, Volker ^a   Roth, Wilfried ^a,b   Beckhove, Philipp ^b   Lichter, Peter ^b   Unterberg, Andreas ^a   Radlwimmer, Bernhard ^a   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GLIOMA CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL SEPARATION; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, INBRED NOD; NEOPLASTIC STEM CELLS; POLYMERASE CHAIN REACTION; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952329017     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1800     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
2. Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs cancer "stem" cells and CD133: What's in the name? Biochem Biophys Res Commun 2007;355:855-859
3. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourinitiating cells. Nature 2006;444:761-765 (Pubitemid 44949605)
4. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
5. BeierD,Hau P, ProescholdtM, et al.CD133 + andCD133 - glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015
6. Wang J, Sakariassen PØ, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761-768
7. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008;14:8205-8212
8. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-1218 (Pubitemid 351977611)
9. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129 (Pubitemid 351377986)
10. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760 (Pubitemid 44949604)
11. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
12. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006;98:1755-1757 (Pubitemid 46017927)
13. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006;17:1620-1624 (Pubitemid 44680880)
14. Chearwae W, Bright JJ. PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 2008;99:2044-2053
15. Aguado T, Carracedo A, Julien B, et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 2007;282:6854-6862 (Pubitemid 47100911)
16. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-3977
17. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med 2005;2:e12. (Pubitemid 40412729)
18. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
19. Vasvari GP, Dyckhoff G, Kashfi F, et al. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer 2007;121:1697-1704 (Pubitemid 47417285)
20. Lichter P, Cremer T, Borden J, Manuelidis L, Ward DC. Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet 1988;80:224-234
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 2005;102:363-370 (Pubitemid 43194089)
23. Giguère V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 1994;15:61-79.
24. Dictus C, Tronnier V, Unterberg A, Herold-Mende CC. Comparative analysis of in vitro conditions for rat adult neural progenitor cells. J Neurosci Methods 2007;161:250-258 (Pubitemid 46466951)
25. Günther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897-2909
26. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934
27. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848 (Pubitemid 44299144)
28. Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006;118:2182-2189
29. Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003;20:65-72. (Pubitemid 38146273)
30. Zang C, Wachter M, Liu H, et al. Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003;65:107-118 (Pubitemid 37521308)
31. Gumireddy K, Sutton LN, Phillips PC, et al. All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Clin Cancer Res 2003;9:4052-4059 (Pubitemid 37204020)
32. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol 2000;50:99-108.
33. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: Are we missing the target? J Natl Cancer Inst 2004;96:583-585
34. Clark PA, Treisman DM, Ebben J, Kuo JS. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn 2007;236:3297-3308 (Pubitemid 350276387)
35. Das A, Banik NL, Ray SK. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 2008;87:9-22.
36. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-1117
37. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007;16:837-847
38. Kaba SE, Kyritsis AP, Conrad C, et al. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid tretinoin. J Neurooncol 1997;34:145-151 (Pubitemid 27271719)
39. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WK. Alltrans-retinoic acid: a phase II Radiation Therapy Oncology Group study RTOG 91-13 in patients with recurrent malignant astrocytoma. J Neurooncol 1997;34:193-200. (Pubitemid 27271726)
40. Defer GL, Adle-Biassette H, Ricolfi F, et al. All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol 1997;34:169-177 (Pubitemid 27271723)
41. Wismeth C, Hau P, Fabel K, et al. Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy-a phase-II study. J Neurooncol 2004;68:79-86. (Pubitemid 39137353)
42. Armstrong JL, Taylor GA, Thomas HD, et al. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer 2007;96:1675-1683
43. Quere R, Baudet A, Cassinat B, et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood 2007;109:4450-4460
44. Chakravarti N, Lotan R, Diwan AH, Warneke CL, Johnson MM, Prieto VG. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res 2007;13:4817-4824
45. Brabender J, Metzger R, Salonga D, et al. Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 2005;26:525-530 (Pubitemid 41214140)
46. Nakayama T, Watanabe M, Yamanaka M, et al. The role of epigenetic modifications in retinoic acid receptor β2 gene expression in human prostate cancers. Lab Invest 2001;81:1049-1057 (Pubitemid 32645980)
47. Hitoshi S, Alexson T, Tropepe V, et al. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev 2002;16:846-858 (Pubitemid 34280108)
48. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-7452 (Pubitemid 44289197)
49. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2009;28:5-16.
50. Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80. (Pubitemid 350309742)